I'm sure you recognize that I was trying to develope a
I'm sure you recognize that I was trying to develope a unified theory of solid tumor cancer. And how leronlimab combined with ici prevents the fake baby from living and growing . It was a pretty lofty goal. That began with a spark from a seemingly offhand comment on another board that I carried out as far as I could and thought it's kind of significant.
I've read hundreds and thousands of various sources and had never read anything like it assembled.
It would be impossible for me to even construct in a hundred years on my own.
So when a response comes back as "we want docs not bots" after presenting something I thought was kind of eye opening (at least for me the whole concept made sense), even if not proven or entirely correct. Not created out of thin air but based on every ccr5 related and semi related study and every Pestell and Pashtoon and Tripathy and Creatv Bio and SMC abstract/poster I could find etc.
I thought, well I can't add anything else to it anyway. My work on it is done. It was where the research road ended I think.
But I also think the core philosophy is correct and know cancer and many other things are not going to be treated effectively without leron being part.
Once the core framework is established it semi transfers directly to other disease categories.
Heck, Paste my whole theory into a chat and ask it some questions.
About neurology or autoimmune or whatever.
It won't automatically have all the underlying studies but it will find connections.
And like you I was tired of listening to bs without any ammunition. Or waiting for someone else to defend leron that knew something.
Those days are over for me.
Nothing can cause doubt
When I read posts asking " do we really know what we own, we really dont know"
I think, "I know exactly what I own".
And I'm doing my best to help share it.
Thanks!
8
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...
Continue Reading
A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...
Continue Reading
A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...
Continue Reading
Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...
Continue Reading
Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...
Continue Reading
AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...
Continue Reading
Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...
Continue Reading
Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...
Continue Reading
A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...
Continue Reading
First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...
Continue Reading
Top 5 Most Recently Viewed Articles
Introduction to LightBox's Findings Recent insights from LightBox reveal significant shifts in the commercial real estate (CRE) sector, highlighting increased activity in response to recent economic changes. As a leading provider of CRE information and technology, LightBox's Monthly CRE Activity Index plays a crucial role in tracking the dynamics of the market....
Continue Reading
Understanding Alliance Pharma's Trading Activity Alliance Pharma plc, known for its strategic positioning in the pharmaceutical market, has made a significant impact through its recent trading activities. These transactions are crucial for understanding the company's current standing and future potential in the market. The firm operates under the stock ticker LSE:INVP,...
Continue Reading
Icon Energy Corp. Welcomes M/V Bravo and Secures Financing Icon Energy Corp. (“Icon”) (Nasdaq: ICON) is thrilled to announce the arrival of its latest fleet member, the M/V Bravo, alongside significant financing aimed at facilitating future growth. This advanced Kamsarmax dry bulk carrier represents a key achievement in Icon's operational strategy, paving the way for...
Continue Reading
Traders braced for turmoil as Coinbase Global, Inc. (NASDAQ: COIN) found itself entangled in a significant class action lawsuit back in 2024, brought forth by the reputable law firm Bronstein, Gewirtz & Grossman. This isn’t just another legal skirmish; it’s an alarm bell ringing loudly for investors who acquired Coinbase securities during the defined Class Period....
Continue Reading
Danny Go! Launches Exciting New Toy Line Three new active-play toys inspired by the beloved YouTube series, Danny Go!, are set to hit shelves just in time for the holiday season. This innovative collaboration between Danny Go! and Just Play, a prominent toy company, aims to engage children through play, song, and dance. Exciting Toy Debut at Walmart The launch of these...
Continue Reading
